Michelson Diagnostics brought in $3.2 million in its Series A2 financing round, planning on using the funds to support its VivoSight device.
England-based Michelson develops and commercializes non-invasive diagnostic and monitoring equipment. The company’s flagship product is the VivoSight OCT scanner, which produces high definition images of the layers of the skin and subsurface features, allowing physicians and dermatologists to make accurate treatment decisions concerning what they see.
The Series A2 round was supported by Octopus Investments, Catapult Venture Managers Ltd and London Business Angels. Michelson plans on using the money to support VivoSight sales in Germany, according to a press release.
“The completion of this financing concludes a year in which we have made real progress, especially in our market access in Germany. We now look forward to a very promising 2014 which will include the publication of Level 1 Clinical Evidence in the diagnosis of NMSC,” CEO Jon Holmes said in prepared remarks.